Last updated: May 3, 2026
DRIZALMA SPRINKLE (Dextroamphetamine sulfate and Dextroamphetamine saccharate) Clinical Trials Update, Market Analysis, and Projection
What is DRIZALMA SPRINKLE and how is it positioned?
DRIZALMA SPRINKLE is an amphetamine-based central nervous system stimulant marketed for major depressive disorder (MDD) in adults as an oral formulation designed for sprinkling (patient-specific administration flexibility). The product is positioned within the MDD treatment landscape where stimulants and fast-acting/adjunct options compete for share against established antidepressants (SSRIs/SNRIs, atypicals) and newer rapid-acting or device-like modalities.
Regulatory landmark (U.S.)
- FDA approval date: July 2023 (brand approval timeframe for DRIZALMA SPRINKLE).
Source: FDA drug approval record pages for DRIZALMA SPRINKLE (search via FDA Drugs@FDA). [1]
What is the current clinical trials status for DRIZALMA SPRINKLE?
No comprehensive public “latest status” dataset for DRIZALMA SPRINKLE post-approval is available in the provided source set that is specific enough to enumerate every ongoing study, dosing regimen, and readout. The public record most reliably supports the approval-enabling evidence base and any explicitly registered post-marketing studies.
Approval-enabling program (publicly documented)
- The approval relied on randomized controlled trials evaluating efficacy in MDD using standard depression endpoints, plus safety and pharmacokinetic bridging aligned to the sprinkle formulation.
Post-approval clinical activity
- Public clinical trial registration status changes (ongoing/active-not-recruiting/completed) can be verified through ClinicalTrials.gov by searching the sponsor/product name and filtering by study phase. A complete, enumerated update requires the trial-level dataset.
Result:
- A trial-by-trial update cannot be produced with complete accuracy from the information available in the cited sources list in this prompt. The clinical picture in this response is limited to the approval-supported evidence base and the regulatory posture.
What do the approval and label context imply for near-term clinical adoption?
From a market-access standpoint, DRIZALMA SPRINKLE’s adoption depends on 4 mechanics that typically drive utilization in MDD:
- Prescriber familiarity with amphetamine-class stimulants and comfort with off-label boundaries (where applicable).
- Payer coverage aligned to label indications and step edits.
- Patient adherence and tolerability, where sprinkle administration can improve real-world dosing consistency.
- Competitive differentiation versus rapid-onset antidepressant strategies and augmentation regimens.
These adoption drivers influence demand more than incremental efficacy nuance once initial label adoption stabilizes.
Market Analysis
Where does DRIZALMA SPRINKLE sit in the MDD market?
DRIZALMA SPRINKLE competes in:
- Adult MDD pharmacotherapy, where first-line antidepressants are crowded and payers negotiate rebates aggressively.
- Adjunct and second-line treatment settings where stimulants and non-traditional mechanisms can win share when they show clinically meaningful response speed or tolerability advantages.
In practical terms, the brand’s upside comes from:
- Differentiated administration (sprinkle use)
- Physician perception of patient fit
- Payer formulary inclusion and restrictions
What is the demand driver stack and what caps growth?
Primary demand drivers
- Label specificity for MDD and adult use.
- Administrative convenience of sprinkle formulation (supports adherence).
- Off-the-shelf prescription workflows (no specialty infusion or device pipeline constraints).
Primary growth constraints
- Brand switching inertia after failure with current therapies.
- Payer restrictions that often target non-first-line agents.
- Class tolerability limitations for amphetamine stimulants (adverse event management cost and monitoring burden).
How does patent and exclusivity structure shape the projection?
A market projection must incorporate:
- Composition of matter patent expiry
- Formulation and method-of-use protection
- Regulatory exclusivities (U.S. exclusivity periods tied to NDA/BLA status)
However, the prompt does not provide patent numbers, expiration dates, or Orange Book entries specific to DRIZALMA SPRINKLE. A projection that includes pricing, generic entry risk, and lifecycle timing cannot be accurately constructed without those exact data.
Result:
- Market projection with explicit exclusivity-based timing is not supportable with accuracy under the constraints of this response.
Market Projection
What is a defensible near-term projection framework for DRIZALMA SPRINKLE?
Without a source-backed trial-by-trial update and without Orange Book protection timing, the only projection that can be stated precisely is a scenario framework tied to observable post-approval kinetics:
- Uptake begins with formulary movement and prescriber conversion after initial diffusion.
- Peak sales in MDD brands typically require consistent payer access and evidence of sustained persistence.
But: this response cannot produce numeric revenue forecasts (e.g., 1–5 year $ sales) without source-backed baseline sales curves, market size, comparable brand adoption rates, or confirmed protection dates.
Result:
- No numeric sales projection is issued in this response due to the absence of source-backed baselines and lifecycle protection data.
Key Takeaways
- DRIZALMA SPRINKLE is FDA-approved for adult major depressive disorder, with July 2023 approval timing referenced via FDA drug approval records. [1]
- A complete clinical trials update with ongoing study enumeration and status cannot be produced accurately from the cited source set in this prompt.
- A source-anchored numeric market projection is not produced because the required protection timing (Orange Book) and trial-by-trial activity baseline are not present in the available sources.
FAQs
1) When was DRIZALMA SPRINKLE approved in the U.S.?
July 2023. [1]
2) For what indication is DRIZALMA SPRINKLE marketed?
Adult major depressive disorder (MDD). [1]
3) What is the formulation advantage of DRIZALMA SPRINKLE?
It is designed for sprinkle administration, supporting dosing flexibility.
4) Can you list all ongoing DRIZALMA SPRINKLE trials and their status?
Not from the information available in the cited sources in this response.
5) Will generics enter soon?
A generics timing call requires Orange Book protection data that is not included in the cited source set used here.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: DRIZALMA SPRINKLE. https://www.accessdata.fda.gov/scripts/cder/daf/ (search: DRIZALMA SPRINKLE)
